Allscripts Healthcare Solutions (MDRX) Set to Announce Quarterly Earnings on Wednesday

Allscripts Healthcare Solutions (NASDAQ:MDRX) will issue its quarterly earnings data after the market closes on Wednesday, February 14th. Analysts expect the company to announce earnings of $0.19 per share for the quarter.

Allscripts Healthcare Solutions (NASDAQ:MDRX) opened at $14.23 on Wednesday. The firm has a market cap of $2,621.68, a P/E ratio of -12.27, a PEG ratio of 2.05 and a beta of 1.18. Allscripts Healthcare Solutions has a 52 week low of $11.25 and a 52 week high of $16.13. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.98 and a current ratio of 0.98.

In related news, President Richard J. Poulton sold 15,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $14.26, for a total value of $213,900.00. Following the completion of the transaction, the president now directly owns 1,351,773 shares of the company’s stock, valued at $19,276,282.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Brian Farley sold 5,000 shares of the firm’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $14.35, for a total transaction of $71,750.00. Following the completion of the transaction, the executive vice president now directly owns 191,607 shares of the company’s stock, valued at $2,749,560.45. The disclosure for this sale can be found here. Insiders sold 56,796 shares of company stock valued at $804,842 over the last three months. 0.91% of the stock is owned by company insiders.

MDRX has been the subject of several research reports. KeyCorp reaffirmed a “hold” rating on shares of Allscripts Healthcare Solutions in a research note on Friday, October 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $17.00 price target on shares of Allscripts Healthcare Solutions in a research note on Monday, January 8th. Maxim Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Allscripts Healthcare Solutions in a research note on Tuesday, January 9th. Zacks Investment Research cut shares of Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, November 8th. Finally, Robert W. Baird raised their price target on shares of Allscripts Healthcare Solutions from $16.00 to $17.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. Allscripts Healthcare Solutions currently has an average rating of “Buy” and a consensus price target of $15.66.

ILLEGAL ACTIVITY NOTICE: “Allscripts Healthcare Solutions (MDRX) Set to Announce Quarterly Earnings on Wednesday” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/07/allscripts-healthcare-solutions-mdrx-set-to-announce-quarterly-earnings-on-wednesday.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Earnings History for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply